2.73
-0.15(-5.21%)
Currency In USD
| Previous Close | 2.88 |
| Open | 2.83 |
| Day High | 2.83 |
| Day Low | 2.7 |
| 52-Week High | 10.16 |
| 52-Week Low | 2.11 |
| Volume | 30,678 |
| Average Volume | 136,072 |
| Market Cap | 7.83M |
| PE | -1.78 |
| EPS | -1.53 |
| Moving Average 50 Days | 2.49 |
| Moving Average 200 Days | 3.14 |
| Change | -0.15 |
If you invested $1000 in Biomerica, Inc. (BMRA) 10 years ago, it would be worth $262.5 as of January 10, 2026 at a share price of $2.73. Whereas If you bought $1000 worth of Biomerica, Inc. (BMRA) shares 5 years ago, it would be worth $66.39 as of January 10, 2026 at a share price of $2.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
GlobeNewswire Inc.
Dec 23, 2025 1:19 PM GMT
CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total healthcare expenditure.The $300 rate will apply to claims approved and paid by Medicare with dates of service on or after Ja
Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio
GlobeNewswire Inc.
Dec 11, 2025 1:08 PM GMT
Authorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection • Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease, and H. pylori infection • Designed for early detection
Biomerica’s inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS
GlobeNewswire Inc.
Nov 25, 2025 1:19 PM GMT
Publication details large multicenter clinical trial demonstrating significant reductions in IBS symptoms through inFoods IBS guided dietary therapy IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider